10 Jan 2024


Trilegal advised JB Pharma on its acquisition of a portfolio of certain opthamalogy brands from Novartis.JB Pharmaceuticals Limited entered into a trademark license agreement with respect to acquisition of a portfolio of certain ophthalmology brands owned by Novartis Innovative Therapies AG. It also entered into a promotion and distribution agreement with Novartis Healthcare Private Limited for the purpose of marketing these brands in the Indian market.
The Trilegal team advising on the matter was led by our Corporate Partners Clarence Anthony and Harsh Maggon and comprised Nidhi Singla, Senior Associate; Shanika Bhowmick and Vivek Vishwanathan, Associates; Vadiraja PS, Principal Consultant..
Media Link:
About Trilegal
Trilegal is one of India’s leading law firms, with expertise across the full spectrum of corporate legal services. Trilegal has offices in four key cities of India.
Trilegal has been recognised as the India Deal Firm of the Year by Asian Legal Business (ALB) India Law Awards 2023; one of the ‘Best Overall Law Firms’ at the India Business Law Journal Indian Law Firm Awards 2022; ‘Firm of the year’ for Client Service Excellence by Asia Law Awards 2021; “M&A Law firm of the Year” by VCCircle Awards 2020 one of the most innovative law firms in Asia in the inaugural edition of ALB Trailblazers 2020; and ‘highly commended’ in the FT RSG Innovative Lawyers Awards 2020.
For more information, please contact:
Sahil Wason
Mob: +91-8928008122 | BD@trilegal.com

Trilegal expands its Intellectual Property practice with the addition of two new Partners

Deal: Trilegal advises Kimbal on its Series B fundraise from GEF Capital Partners and Niveshaay Sambhav Fund

Deal: Trilegal advised Skyroot Aerospace on its ~US$60 million fundraise co-led by Sherpalo and GIC, with participation from Funds managed by BlackRock and other investors
Under the rules of the Bar Council of India, Trilegal is prohibited from soliciting work or advertising in any form or manner. By accessing this website, www.trilegal.com, you acknowledge that:
We prioritize your privacy. Before proceeding, we encourage you to read our privacy policy, which outlines the below, and terms of use to understand how we handle your data:
For more information, please read our terms of use and our privacy policy.